Ariad Pharmaceuticals Inc
ARIA
ARIA was delisted on the 15th of February, 2017.
169 hedge funds and large institutions have $790M invested in Ariad Pharmaceuticals Inc in 2014 Q2 according to their latest regulatory filings, with 27 funds opening new positions, 63 increasing their positions, 44 reducing their positions, and 29 closing their positions.
43% more repeat investments, than reductions
Existing positions increased: 63 | Existing positions reduced: 44
19% more call options, than puts
Call options by funds: $31.5M | Put options by funds: $26.5M
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
7% less first-time investments, than exits
New positions opened: 27 | Existing positions closed: 29
1% less funds holding
Funds holding: 171 → 169 (-2)
10% less capital invested
Capital invested by funds: $877M → $790M (-$86.6M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AQR Capital Management
Greenwich,
Connecticut
|
+$20.4M |
| 2 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$19.5M |
| 3 |
Renaissance Technologies
New York
|
+$14.8M |
| 4 |
Norges Bank
Oslo,
Norway
|
+$14.6M |
| 5 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$13.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SPC
Slate Path Capital
New York
|
-$53.4M |
| 2 |
PAI
Palo Alto Investors
Palo Alto,
California
|
-$8.14M |
| 3 |
ARTA
A.R.T. Advisors
New York
|
-$4.58M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$3.23M |
| 5 |
Allianz Asset Management
Munich,
Germany
|
-$2.81M |
ARIA Hedge Fund Activity: Q2 2014 in Review
169 of the 3,491 institutional investors tracked by Wall St. Rank reported a position in Ariad Pharmaceuticals Inc (ARIA) for Q2 2014, worth a combined $790M — down 9.9% from $877M a quarter earlier.
Sellers outnumbered buyers: 29 funds closed out of ARIA and 27 opened new positions — a net loss of 2 holders — while 44 trimmed existing stakes and 63 added.
The largest buyer was AQR Capital Management, adding an estimated $20.4M. The largest seller was Slate Path Capital, exiting entirely with an estimated $53.4M sold.
- 169 institutional investors held Ariad Pharmaceuticals Inc (ARIA) as of Q2 2014, down from 171 in Q1 2014.
- Funds reported $790M of Ariad Pharmaceuticals Inc stock for Q2 2014, down 9.9% quarter-over-quarter.
- 27 funds opened new Ariad Pharmaceuticals Inc positions in Q2 2014 and 29 closed out, a net change of -2 holders.
- The largest Ariad Pharmaceuticals Inc buyer in Q2 2014 was AQR Capital Management, an estimated $20.4M added.
- The largest Ariad Pharmaceuticals Inc seller in Q2 2014 was Slate Path Capital, an estimated $53.4M sold.
Based on aggregated 13F filings for Q2 2014.